SREBF1 and metabolic dysfunction-associated steatotic liver disease: NAFLD is characterised by increase in hepatic TG synthesis, mediated by SREBP1c dependent or fructose driven lipogenesis,2 and therapeutic targets are in development to treat NAFLD acting on this pathway.30 31 With our findings, we have identified a novel pathway for TG synthesis mediated by a faster PI metabolism.